Adding pertuzumab to existing treatments after surgery for early breast cancer not cost effective, says NICE in draft guidance
Women with a type of early breast cancer may not benefit from continuing or starting a drug after having surgery, NICE says in draft guidance.
Latest news headlines
NICE says more people should be able to freely access pembrolizumab, known as Keytruda, after a new trial shows it helps certain adults with lung cancer live more than a year longer.
06 June 2018
Reductions to the price of three multiple sclerosis (MS) drugs mean NICE is now able to recommend them for routine NHS funding.
14 May 2018
NICE has published new guidance to help healthcare professionals optimise the treatment of urinary tract infections (UTIs).
08 May 2018
NICE has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.
04 May 2018
NICE has published draft guidance in which dinutuximab beta is not recommended as a treatment for high-risk neuroblastoma – a rare type of cancer that mainly affects children and young people.
04 May 2018
NICE has announced that Meindert Boysen has been appointed as its director of the Centre for Health Technology Evaluation.
26 April 2018